secwatch.observer — SEC 8-K summary
======================================

Issuer:     GLAUKOS Corp (GKOS)
CIK:        0001192448
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0001558370-24-010478
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glaukos reports record Q2 sales $95.7M (+19% YoY), raises FY2024 guidance
-------------------------------------------------------------------------

- Record net sales of $95.7M, up 19% reported / 20% constant currency YoY.
- Glaucoma segment sales $75.9M (+23% YoY); Corneal Health $19.8M (+7% YoY).
- GAAP net loss $53.9M ($1.06 loss per share) vs $32.8M ($0.68) in Q2 2023.
- Non-GAAP net loss $26.3M ($0.52 loss per share) improved from $26.6M ($0.55) prior year.
- FY2024 net sales guidance raised to $370M–$376M from $357M–$365M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1192448/000155837024010478/0001558370-24-010478-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1192448/000155837024010478/gkos-20240731x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-010478

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer